| |
|
|
|
|
|
 |
| |
|
Á§½ºÆ®(¼Ò¾Æ¿ë) JEXT
|
Àü¹®ÀǾàǰ | »èÁ¦ | Èñ±ÍÀǾàǰ | ºÐ¾÷¿¹¿ÜÀǾàǰ(45)
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
664000311
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/0.15mL/ŰƮ(2020.02.01)(ÇöÀç¾à°¡)
\134,933 ¿ø/0.15mL/ŰƮ(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| ÁÖ¼ººÐÄÚµå |
483930BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806640003102 |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¾Ë·¯Áö ¹ÝÀÀ(¾Æ³ªÇʶô½Ã½º)ÀÇ ÀÀ±Þóġ
°ïÃæ ħ ¶Ç´Â ¹°¸², À½½Ä, ¾à¹°°ú ´Ù¸¥ Ç׿ø ¹× Ư¹ß¼º ¶Ç´Â ¿îµ¿-À¯µµ ¾Æ³ªÇʶô½Ã½º
ÀÌ ¾àÀº ¾Æ³ªÇʶôƽ ¹ÝÀÀ °æÇèÀÌ ÀÖ´Â »ç¶÷¿¡°Ô Áï½Ã ÀÚ°¡-Åõ¿©¸¦ ¸ñÀûÀ¸·Î ÇÑ´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
±ÙÀ°ÁÖ»ç·Î¼ ¾Ë·¯Áö ÀÀ±ÞÁõ»ó¿¡ ´ëÇÑ ¼ºÀÎ ¿ë·®Àº 0.3¹Ð¸®±×¶÷ÀÌ´Ù.
¼Ò¾ÆÀÇ ÀûÁ¤ Åõ¿©·®Àº üÁß ÀÇÁ¸ÀûÀ¸·Î 0.15¹Ð¸®±×¶÷ ¶Ç´Â 0.30¹Ð¸®±×¶÷À̸ç, üÁß 1kg ´ç 0.01¹Ð¸®±×¶÷ÀÇ Åõ¿©°¡ ÃßõµÈ´Ù.
üÁß 30kg ÀÌÇÏÀÇ È¯ÀÚ¿¡°Ô´Â 0.15¹Ð¸®±×¶÷ ¿ë·®ÀÌ Á¦°øµÇÁö¸¸, ó¹æÇÏ´Â Àǻ簡 ÁÖÀÇ °üÂûÇÏ¿© Áõ·® ¶Ç´Â °¨·®ÇÒ ¼ö ÀÖ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[º¸±â]
|
| ±Ý±â |
»ý¸íÀÌ À§±ÞÇÑ »óȲ¿¡¼ ¿¡Çdz×ÇÁ¸°À» »ç¿ëÇÔ¿¡ ÀÖ¾î¼ ±Ý±â»çÇ×Àº ¾ø´Ù.
|
| ÀϹÝÀû ÁÖÀÇ |
½ÉÀ庴À» °¡Áø ȯÀÚµéÀº ƯÈ÷ ÁÖÀÇÇØ¾ß ÇÑ´Ù.
½ÉÀ庴¿¡ »ç¿ëÇÏ´Â µð±âÅ»¸®½º, ¼öÀº ÀÌ´¢Á¦, Äû´Ïµò°ú ÇÔ²² »ç¿ëÇÏÁö ¾Ê´Â´Ù.
´ÙÀ½ÀÇ °æ¿ì ¿¡Çdz×ÇÁ¸° Åõ¿© ÈÄ ºÎÀÛ¿ëÀÌ ½ÉÇϹǷΠÁÖÀÇÇØ¾ß ÇÑ´Ù.
¨ç °©»ó¼± ±â´É Ç×Áø ȯÀÚ
¨è ½ÉÇ÷°ü°è ÁúȯÀ» °¡Áø ȯÀÚ
¨é °íÇ÷¾Ð ȯÀÚ
¨ê ´ç´¢º´ ȯÀÚ
¨ë ÁßÀå³âÃþ
¨ì ÀÓ»êºÎ
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
1. 15-30¡É(59-86¢µ) º¸°ü
2. ºû¿¡ ³ëÃâµÇÁö ¾Êµµ·Ï ÇÒ °Í
3. ³ÃÀå°í¿¡¼ º¸°üÇÏÁö ¸» °Í
4. ¿Âµµ°¡ ¾ÆÁÖ ³·°Å³ª ³ôÀº °÷¿¡ µÎÁö ¸» °Í |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Epinephrine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Epinephrine works via the stimulation of alpha and beta-1 adrenergic receptors, and a moderate activity at beta-2 adrenergic receptors.
|
| Pharmacology |
Epinephrine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Epinephrine is indicated for intravenous injection in treatment of acute hypersensitivity, treatment of acute asthmatic attacks to relieve bronchospasm, and treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome). The actions of epinephrine resemble the effects of stimulation of adrenergic nerves. To a variable degree it acts on both alpha and beta receptor sites of sympathetic effector cells. Its most prominent actions are on the beta receptors of the heart, vascular and other smooth muscle. When given by rapid intravenous injection, it produces a rapid rise in blood pressure, mainly systolic, by (1) direct stimulation of cardiac muscle which increases the strength of ventricular contraction, (2) increasing the heart rate and (3) constriction of the arterioles in the skin, mucosa and splanchnic areas of the circulation. When given by slow intravenous injection, epinephrine usually produces only a moderate rise in systolic and a fall in diastolic pressure. Although some increase in pulse pressure occurs, there is usually no great elevation in mean blood pressure. Accordingly, the compensatory reflex mechanisms that come into play with a pronounced increase in blood pressure do not antagonize the direct cardiac actions of epinephrine as much as with catecholamines that have a predominant action on alpha receptors.
|
| Metabolism |
Epinephrine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Absorption |
Epinephrine¿¡ ´ëÇÑ Absorption Á¤º¸ Usually this vasodilator effect of the drug on the circulation predominates so that the modest rise in systolic pressure which follows slow injection or absorption is mainly the result of direct cardiac stimulation and increase in cardiac output.
|
| Pharmacokinetics |
EpinephrineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ±â°üÁö ÀÌ¿Ï È¿°úÀÇ ¹ßÇö½Ã°£
- ÇÇÇÏÁÖ»ç : 5-10ºÐ À̳»
- ÈíÀÔ : 1ºÐ À̳»
- °á¸· Á¡Àû
- È¿°ú¹ßÇö½Ã°£ (¾È¾Ð °¨¼Ò) : 1½Ã°£ À̳»
- ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£ : 4-8½Ã°£ À̳»
- ´«¿¡ ´ëÇÑ ÀÛ¿ëÁö¼Ó½Ã°£ : 12-24 ½Ã°£
- Èí¼ö : °æ±¸ Åõ¿©½Ã À§Àå°ü, °£¿¡¼ ½Å¼ÓÈ÷ ´ë»çµÇ¹Ç·Î ¾à¸®ÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Á߳󵵿¡ µµ´ÞÇÏÁö ¸øÇÔ
- ºÐÆ÷ : ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ
- ´ë»ç : Åõ¿© ÈÄ ¾Æµå·¹³¯¸°¼º ½Å°æ¼¼Æ÷¿¡ uptakeµÇ¾î monoamine oxidase¿Í catechol-o-methyltransferase¿¡ ÀÇÇØ ´ë»çµÊ. ¼øÈ¯ ¾à¹°Àº °£¿¡¼ ´ë»çµÊ
- ¼Ò½Ç : ºñȰ¼ºÇü ´ë»çü (metanephrine, mandelic acidÀÇ È²»ê ¶Ç´Â ¼ö»êÈ À¯µµÃ¼)¿Í ¼Ò·®Àº ¹Ìº¯Èü·Î ´¢¸¦ ÅëÇØ ¹è¼³µÊ
|
| Toxicity |
Epinephrine¿¡ ´ëÇÑ Toxicity Á¤º¸ Skin, LD50 = 62 mg/kg (rat)
|
| Drug Interactions |
Epinephrine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol Hypertension, then bradycardiaAlseroxylon Increased arterial pressureAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectAtenolol Hypertension, then bradycardiaBetaxolol Hypertension, then bradycardiaBevantolol Hypertension, then bradycardiaBisoprolol Hypertension, then bradycardiaCarteolol Hypertension, then bradycardiaCarvedilol Hypertension, then bradycardiaClomipramine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDeserpidine Increased arterial pressureDoxepin The tricyclic increases the sympathomimetic effectEntacapone Entacapone increases the effect and toxicity of sympathomimeticsMethylergonovine Possible marked increase of arterial pressureNortriptyline The tricyclic increases the sympathomimetic effectProtriptyline The tricyclic increases the sympathomimetic effectImipramine The tricyclic increases the sympathomimetic effectEsmolol Hypertension, then bradycardiaGuanethidine The agent decreases the effect of guanethidineIsocarboxazid Increased arterial pressureLabetalol Hypertension, then bradycardiaLinezolid Possible increase of arterial pressureMethyldopa Increased arterial pressureMetoprolol Hypertension, then bradycardiaMidodrine Increased arterial pressureMoclobemide Moclobemide increases the sympathomimetic effectNadolol Hypertension, then bradycardiaPenbutolol Hypertension, then bradycardiaOxytocin Possible marked increase of arterial pressurePhenelzine Increased arterial pressurePindolol Hypertension, then bradycardiaPractolol Hypertension, then bradycardiaPropranolol Hypertension, then bradycardiaRasagiline Increased arterial pressureReserpine Increased arterial pressureSotalol Hypertension, then bradycardiaTimolol Hypertension, then bradycardiaTranylcypromine Increased arterial pressureTrimipramine The tricyclic increases the sympathomimetic effectErgonovine Possible marked increase of arterial pressureOxprenolol Hypertension, then bradycardiaPargyline Increased arterial pressure
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Epinephrine¿¡ ´ëÇÑ Description Á¤º¸ The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem]
|
| Dosage Form |
Epinephrine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntramuscularLiquid OralSolution IntramuscularSolution IntravenousSolution NasalSolution Respiratory (inhalation)Solution / drops OphthalmicSolution / drops Oral
|
| Drug Category |
Epinephrine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic AgonistsAdrenergic alpha-AgonistsAdrenergic beta-AgonistsBronchodilator AgentsMydriaticsSympathomimeticsVasoconstrictor Agents
|
| Smiles String Canonical |
Epinephrine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CNCC(O)C1=CC(O)=C(O)C=C1
|
| Smiles String Isomeric |
Epinephrine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CNC[C@H](O)C1=CC(O)=C(O)C=C1
|
| InChI Identifier |
Epinephrine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1
|
| Chemical IUPAC Name |
Epinephrine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4-[(1R)-1-hydroxy-2-methylaminoethyl]benzene-1,2-diol
|
| Drug-Induced Toxicity Related Proteins |
EPINEPHRINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Interleukin-8 Drug:epinephrine Toxicity:inflammation. [¹Ù·Î°¡±â] Replated Protein:Leptin Drug:epinephrine Toxicity:epinephrine-induced suppression in human obesity. [¹Ù·Î°¡±â] Replated Protein:Glutathione reductase Drug:epinephrine Toxicity:cytotoxic. [¹Ù·Î°¡±â] Replated Protein:Alpha-2A adrenergic receptor Drug:epinephrine Toxicity:platelet aggregation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-02-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|